1-(4-fluorophenyl)adamantane | 59974-37-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-fluorophenyl)adamantane
• 英文别名: 1-(p-Fluorphenyl)-adamantan；1-p-Fluorophenyladamantane
• CAS: 59974-37-7
• 化学式: C₁₆H₁₉F
• 分子量: 230.325
• InChiKey: PEARESWMUKMNOF-UHFFFAOYSA-N

物化性质

• 熔点：
  74-75 °C
• 沸点：
  307.3±21.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-溴金刚烷 、 氟苯 在 palladium on activated charcoal potassium carbonate 作用下， 反应 12.0h， 以56%的产率得到1-(4-fluorophenyl)adamantane
  参考文献：
  名称：

  Braese, Stefan; Waegell, Bernard; Meijere, Armin de, Synthesis, 1998, # 2, p. 148 - 152

  摘要：

  DOI：

文献信息

• Nickel‐Catalyzed Cross‐Coupling of Aryl Bromides with Tertiary Grignard Reagents Utilizing Donor‐Functionalized N‐Heterocyclic Carbenes (NHCs)
  作者：Claudia Lohre、Thomas Dröge、Congyang Wang、Frank Glorius

  DOI：10.1002/chem.201100909

  日期：2011.5.23

  substrates represents a major challenge of the present cross‐coupling methodology. The nickel‐catalyzed Kumada cross‐ coupling of tertiary alkyl Grignard reagents with aryl bromides allows this difficult reaction with numerous different substrates. Optimal results were obtained using sterically demanding, bifunctional N‐heterocyclic carbene ligands.

  一二三 空间位阻烷基底物的利用代表了目前交叉偶联方法的主要挑战。叔烷基格氏试剂与芳基溴的镍催化的Kumada交联使得这种困难的反应可与多种不同的底物进行。使用空间要求高的双功能N杂环卡宾配体可获得最佳结果。
• Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
  申请人：Battista Kathleen

  公开号：US20060030577A1

  公开（公告）日：2006-02-09

  The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.

  本发明涉及一种新的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸酮衍生物，其通式如下： 其中所有变量如本文所定义，可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和病症。更具体地，本发明的化合物可用于治疗焦虑、抑郁、惊恐、痴呆、躁狂、双相障碍、物质滥用、神经病性疼痛、急性疼痛、慢性疼痛、偏头痛、哮喘、咳嗽、精神病、精神分裂症、癫痫、高血压、肥胖症、进食障碍、渴望、糖尿病、心脏心律失常、肠易激综合征、克罗恩病、尿失禁、肾上腺疾病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、阿尔茨海默病，以改善认知或记忆，并用于情绪稳定。
• HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS
  申请人：BATTISTA Kathleen

  公开号：US20090124614A1

  公开（公告）日：2009-05-14

  The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.

  本发明涉及一种新型的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸酮衍生物，其通式如下：其中所有变量均如本文所定义，可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和症状。更具体地，本发明的化合物可用于治疗焦虑、抑郁、惊恐、痴呆、躁狂、双相情感障碍、物质滥用、神经病性疼痛、急性疼痛、慢性疼痛、偏头痛、哮喘、咳嗽、精神病、精神分裂症、癫痫、高血压、肥胖症、进食障碍、渴望、糖尿病、心律失常、肠易激综合征、克罗恩病、尿失禁、肾上腺疾病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、阿尔茨海默病，以改善认知或记忆，并用于情绪稳定。
• Indium-Catalyzed Friedel-Crafts Alkylation of Monosubstituted Benzenes by 1-Bromoadamantane
  作者：Paul Mosset、René Grée

  DOI：10.1055/s-0032-1316909

  日期：——

  Indium salts such as InCl3 and InBr3 (ca. 1-5 mol%) efficiently catalyzed the Friedel-Crafts reaction of 1-bromoadamantane with benzene and monosubstituted benzenes to give 1-adamantyl benzenes. Indium bromide enabled faster reactions than indium chloride but the latter was more suitable in the case of halobenzenes.
• PERKINS R.; BENNETT SH.; BOWERING E.; BURKE J.; REID K.; WALL D., CHEM. AND IND., 1980, NO 19, 790,
  作者：PERKINS R.、 BENNETT SH.、 BOWERING E.、 BURKE J.、 REID K.、 WALL D.

  DOI：——

  日期：——